Determining the subjective effects of TFMPP in human males.
Reem K Jan, Joanne C Lin, HeeSeung Lee, Janie L Sheridan, Rob R Kydd, Ian J. Kirk, Bruce R. Russell
Psychopharmacology August 2010 DOI: 10.1007/s00213-010-1911-y (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Randomized controlled trial Placebo-controlled Double-blind Peer reviewed |
|---|---|
| Sample size | 30 |
| Population | Healthy, non-smoking male volunteers, mean age 24 +/- 4 years |
| Intervention | TFMPP |
| Dose | 60 mg |
| Measures | Addiction Research Centre Inventory (ARCI), Profile of Mood States (POMS), Visual Analogue Scales (VAS) |
| Key findings | TFMPP 60 mg produced increases in 'dysphoria', 'dexamphetamine-like effects', 'tension/anxiety', 'confusion/bewilderment', 'drug liking', 'high', and 'stimulated' ratings relative to placebo, suggesting a profile resembling amphetamine-type stimulants and serotonergic drugs. |
Abstract
Trifluoromethylphenyl piperazine (TFMPP) is an active constituent of a relatively new group of recreational drugs known as 'party pills'. TFMPP has been anecdotally reported to induce mild psychedelic effects similar to lysergic acid diethylamide and psilocybin. There has been no research about the subjective effects of TFMPP in humans. This study aimed to investigate the subjective effects of TFMPP in human males. A randomised, double-blind, placebo-controlled trial design was used to investigate the subjective effects of TFMPP in 30 healthy, non-smoking male volunteers (mean age 24 +/- 4 years). Participants were randomised into two groups and given either TFMPP 60 mg (n = 15) or placebo (n = 15). Each participant completed three rating scales, the Addiction Research Centre Inventory (ARCI), the Profile of Mood States (POMS) and the Visual Analogue Scales (VAS), both before and 120 min after drug administration. Results from the ARCI indicated that TFMPP produced increases in 'dysphoria' and 'dexamphetamine-like effects'. TFMPP also increased ratings of 'tension/anxiety' and 'confusion/bewilderment' as rated on the POMS. Results from the VAS indicated increases in 'drug liking', 'high' and 'stimulated' ratings relevant to placebo. Increased ratings of 'dexamphetamine-like effects', 'tension/anxiety', 'stimulated' and 'high' following TFMPP administration resemble the subjective effects of common amphetamine-type stimulants. However, increases in 'dysphoria' and 'confusion/bewilderment' ratings following TFMPP are more commonly associated with drugs that have greater effects on serotonin release, binding and reuptake such as 1-[3-chlorophenyl]-piperazine, fenfluramine and lysergic acid diethylamide.
Citations in the library
Cited by 10
- Clinical toxicology of newer recreational drugs Clinical Toxicology October 1, 2011
- Novel psychoactive substances (designer drugs): overview and pharmacology of modulators of monoamine signalling Swiss Medical Weekly January 11, 2015
- Subjective effects in humans following administration of party pill drugs BZP and TFMPP alone and in combination Drug Testing and Analysis April 28, 2011
- Measuring the subjective: revisiting the psychometric properties of three rating scales that assess the acute effects of hallucinogens. Human Psychopharmacology: Clinical and Experimental September 1, 2016
- Can psilocybin be safely administered under medical supervision? A systematic review of adverse event reporting in clinical trials Drug Science, Policy and Law 2022
and 5 more in the library
Cites 3
- Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin Synapse 2000
- The behavioral pharmacology of hallucinogens. Biochemical Pharmacology July 20, 2007
- Reinforcing, subjective, and physiological effects of MDMA in humans: a comparison with d-amphetamine and mCPP. Drug and Alcohol Dependence October 1, 2003